^
Association details:
| Biomarker: | AR-V7 positive |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | abiraterone acetate (CYP17A1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
650P - Comparing the predictive value of exosome, circulating tumor cells, and tumor tissue in detecting AR-V7 among metastatic castration-resistant prostate cancer treated with abiraterone
Published date:
09/14/2020
Excerpt:
...Positive AR-V7 detected in exosome was associated with shorter bPFS compared with AR-V7 negative patients (HR 4.08, 95%CI 1.13-14.69, P=0.03). However, AR-V7 positivity in tumor tissue and CTC failed to predict clinical prognosis in mCRPC treated with abiraterone....The positivity of AR-V7 in plasma-derived exosomes outperforms CTC and tumor tissue as a predictor of primary resistance in mCRPC patients treated with abiraterone.
